Sept. 12, 2019: Better virologic outcomes at coordinated walk-in facilities offering incentives; same-day PrEP initiation at STD clinics; U=U and "low drug regimens"; adherence trends among perinatally infected adolescents.
Aug. 29, 2019: Viral load blips, low-level viremia, and eventual virologic failure; pinpointing non-adherence as a cause of HIV treatment failure; HIV care costs vary widely throughout U.S.; Kaposi sarcoma incidence in the modern HIV treatment era.
Aug. 15, 2019: PCP continuity, ID specialization, and adherence; rules of HIV patient engagement; long-term benefits of financial incentives on adherence; headaches and TDF/FTC.
Researchers reported hopeful news on regimens with lower treatment burdens and newly developed antiretrovirals.
Aug. 1, 2019: Raltegravir OK in pregnancy; HIV disclosure and viral suppression among pregnant women; newborn size following HIV exposure; causes of hearing problems among people with HIV.
Steven Deeks, M.D., talks about the medical community's hopes, inspirations, and unanswered questions regarding research for an HIV cure.
July 25, 2019: Challenges in viral suppression for young, black women; stigma's impact on women's health; generalized anxiety disorder screening needed; how depression harms the brain.
World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy
New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.
Having Fallen Out of Care, Most Gay and Bisexual Men With Detectable HIV Viral Loads Were Successfully Reconnected, Study Finds
The study enrolled more than a thousand people in four U.S. cities: Atlanta, Baltimore, Birmingham, and Boston.
July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.